The early longitudinal course of cognitive deficits in schizophrenia

Journal of Clinical Psychiatry

Volumn 75, Issue SUPPL. 2, 2014, Pages 25-29

  Nuechterlein, Keith H ^a,b   Ventura, Joseph ^a   Subotnik, Kenneth L ^a   Bartzokis, George ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE; MYELIN;

ARTICLE; COGNITIVE DEFECT; COGNITIVE THERAPY; DISABILITY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; FRONTAL LOBE; FUNCTIONAL STATUS; HUMAN; MEDICATION COMPLIANCE; MYELINATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SCHIZOPHRENIA; BRAIN TISSUE; HIGH RISK PATIENT; MENTAL PATIENT; OUTCOME ASSESSMENT; PREDICTION;

COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 84904569387     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13065su1.06     Document Type: Article

References (11)

1. Cornblatt B, Obuchowski M, Roberts S, et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol. 1999;11(3):487-508. doi:10.1017/S09545794902175 PubMed
2. Nuechterlein KH, Dawson ME, Gitlin M, et al. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr Bull. 1992;18(3):387-425. doi:10.1093/schbul/18.3.387 PubMed
3. Hoff AL, Sakuma M, Wieneke M, et al. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry. 1999;156(9):1336-1341. PubMed (Pubitemid 29416528)
4. Allott K, Liu P, Proffitt TM, et al. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res. 2011;125(2-3):221-235. doi:10.1016/j.schres.2010.1.01 PubMed
5. Nuechterlein KH, Subotnik KL, Green MF, et al. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull. 2011;37(suppl 2):S33-S40. doi:10.1093/schbul/sbr084 PubMed
6. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56(5):301-307. doi:10.1016/j.biopsych.204.06.023 PubMed (Pubitemid 39164514)
7. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213. doi:10.176/api.ajp.207.0701042 PubMed (Pubitemid 351704520)
8. Nuechterlein KH, Ventura J, Subotnik KL, et al. Cognitive remediation in the initial phase of schizophrenia. Paper presented at the Cognitive Remediation in Psychiatry Conference; June 8, 2012; New York, NY.
9. Bartzokis G, Lu PH, Stewart SB, et al. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr Res. 2009;113(2-3):322-331. doi:10.1016/j.schres. 209.06.014 PubMed
10. Bartzokis G, Lu PH, Raven EP, et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res. 2012;140(1-3):122-128. doi:10.1016/j.schres.2012. 06.036 PubMed
11. Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72(1):29-39. doi:10.1016/j.schres.204.09.07 PubMed (Pubitemid 39452903)